Stock Price Movement and Market Context
On 30 Dec 2025, Sanofi Consumer Healthcare’s stock recorded an intraday low of Rs 4,386.6, down 4.37% for the day, closing just 1.13% above its 52-week low of Rs 4,360.3. This decline represents an underperformance of 3.85% relative to the previous trading session and lagged the Pharmaceuticals & Biotechnology sector by 3.8%. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained downward momentum.
In contrast, the broader market indices showed relative stability. The Nifty index closed marginally lower at 25,938.85, down 0.01%, and remains 1.49% below its 52-week high of 26,325.80. The Nifty continues to trade above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend in the broader market. Large-cap stocks led the market, with the Nifty Next 50 posting a slight gain of 0.04% on the day.
Financial Performance and Valuation Metrics
Sanofi Consumer Healthcare’s one-year stock performance shows a decline of 10.27%, contrasting sharply with the Sensex’s positive return of 8.21% over the same period. The stock’s 52-week high was Rs 5,894.5, highlighting the extent of the recent price erosion.
The company’s valuation metrics have raised concerns among market participants. Despite a robust return on equity (ROE) of 83.6%, the stock carries a very high price-to-book (P/B) ratio of 41.2, indicating an expensive valuation relative to its book value. This elevated valuation has been difficult to justify in light of the company’s recent profit trends.
Profitability has seen a contraction, with net profits falling by 27% over the past year. This decline in earnings has contributed to the stock’s underperformance and the recent downgrade in its Mojo Grade from Hold to Sell as of 28 Oct 2025. The Mojo Score currently stands at 43.0, reflecting a cautious stance on the stock’s near-term prospects.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Long-Term Growth and Operational Highlights
Despite recent price pressures, Sanofi Consumer Healthcare exhibits several positive operational metrics. The company has maintained a high management efficiency, with an ROE of 76.98% reported in recent periods. Its average debt-to-equity ratio remains at zero, indicating a debt-free capital structure that reduces financial risk.
Long-term growth trends remain healthy, with net sales expanding at an annualised rate of 95.70% and operating profit growing at 83.94%. The latest quarterly results for September 2025 showed a highest-ever profit after tax (PAT) of Rs 62.90 crore and net sales of Rs 233.90 crore, representing a 29.2% increase compared to the previous four-quarter average. The company’s PBDIT for the quarter also reached a record Rs 85.00 crore.
Institutional investors hold a significant stake of 20.15%, reflecting confidence from entities with extensive analytical resources and a focus on fundamentals.
Holding Sanofi Consumer Healthcare India Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Comparative Performance and Market Position
Sanofi Consumer Healthcare’s stock has consistently underperformed its benchmark indices over the last three years. Alongside the 10.27% negative return in the past year, the stock has lagged the BSE500 index in each of the last three annual periods. This persistent underperformance contrasts with the company’s strong sales growth and operational metrics, suggesting valuation pressures and profit declines have weighed heavily on investor sentiment.
The Pharmaceuticals & Biotechnology sector, while facing its own challenges, has generally outperformed Sanofi Consumer Healthcare’s stock in recent months. The company’s market capitalisation grade stands at 3, reflecting a mid-tier valuation relative to peers.
Summary of Key Metrics
To summarise, Sanofi Consumer Healthcare India Ltd’s stock has reached a 52-week low near Rs 4,360.3, reflecting a combination of profit contraction, high valuation multiples, and sustained underperformance relative to benchmarks. The company’s strong sales growth, high management efficiency, and debt-free balance sheet provide a backdrop of operational strength amid the price decline. Institutional ownership remains significant, underscoring continued interest from informed investors.
While the broader market and sector indices maintain generally positive trends, Sanofi Consumer Healthcare’s stock continues to trade below all major moving averages, signalling ongoing price pressure. The downgrade in its Mojo Grade to Sell and a Mojo Score of 43.0 further highlight the cautious market stance on the stock’s near-term outlook.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
